Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice by Susana Mingote et al.
ORIGINAL RESEARCH
published: 08 January 2016
doi: 10.3389/fnsys.2015.00165
Frontiers in Systems Neuroscience | www.frontiersin.org 1 January 2016 | Volume 9 | Article 165
Edited by:
Mikhail Lebedev,
Duke University, USA
Reviewed by:
Gregg Stanwood,
Florida State University, USA
Kenji Tanigaki,
Shiga Medical Center, Japan
*Correspondence:
Stephen Rayport
stephen.rayport@columbia.edu
†
These authors have contributed
equally to this work.
Received: 29 August 2015
Accepted: 12 November 2015
Published:
Citation:
Mingote S, Masson J, Gellman C,
Thomsen GM, Lin C-S, Merker RJ,
Gaisler-Salomon I, Wang Y, Ernst R,
Hen R and Rayport S (2016) Genetic
Pharmacotherapy as an Early CNS
Drug Development Strategy: Testing
Glutaminase Inhibition for
Schizophrenia Treatment in Adult
Mice. Front. Syst. Neurosci. 9:165.
doi: 10.3389/fnsys.2015.00165
Genetic Pharmacotherapy as an
Early CNS Drug Development
Strategy: Testing Glutaminase
Inhibition for Schizophrenia
Treatment in Adult Mice
Susana Mingote 1, 2 †, Justine Masson 1, 3 †, Celia Gellman 1, Gretchen M. Thomsen 1,
Chyuan-Sheng Lin 4, Robert J. Merker 5, Inna Gaisler-Salomon 1, 6, Yvonne Wang 2,
Rachel Ernst 2, René Hen 5, 7 and Stephen Rayport 1, 2*
1Department of Psychiatry, Columbia University, New York, NY, USA, 2Department of Molecular Therapeutics, New York
State Psychiatric Institute, New York, NY, USA, 3Centre de Psychiatrie et Neurosciences, Institut National de la Santé et de la
Recherche Médicale UMR 894 and Université Paris Descartes, Paris, France, 4Department of Pathology and Cell Biology,
Columbia University, New York, NY, USA, 5Department of Integrative Neuroscience, New York State Psychiatric Institute,
New York, NY, USA, 6 Psychobiology Labs, Department of Psychology, University of Haifa, Haifa, Israel, 7Departments of
Neuroscience and Pharmacology, Columbia University, New York, NY, USA
Genetic pharmacotherapy is an early drug development strategy for the identification
of novel CNS targets in mouse models prior to the development of specific ligands.
Here for the first time, we have implemented this strategy to address the potential
therapeutic value of a glutamate-based pharmacotherapy for schizophrenia involving
inhibition of the glutamate recycling enzyme phosphate-activated glutaminase. Mice
constitutively heterozygous for GLS1, the gene encoding glutaminase, manifest a
schizophrenia resilience phenotype, a key dimension of which is an attenuated locomotor
response to propsychotic amphetamine challenge. If resilience is due to glutaminase
deficiency in adulthood, then glutaminase inhibitors should have therapeutic potential.
However, this has been difficult to test given the dearth of neuroactive glutaminase
inhibitors. So, we used genetic pharmacotherapy to ask whether adult induction of GLS1
heterozygosity would attenuate amphetamine responsiveness. We generated conditional
floxGLS1 mice and crossed them with global CAGERT2cre/+ mice to produce GLS1
iHET mice, susceptible to tamoxifen induction of GLS1 heterozygosity. One month
after tamoxifen treatment of adult GLS1 iHET mice, we found a 50% reduction in
GLS1 allelic abundance and glutaminase mRNA levels in the brain. While GLS1 iHET
mice showed some recombination prior to tamoxifen, there was no impact on mRNA
levels. We then asked whether induction of GLS heterozygosity would attenuate the
locomotor response to propsychotic amphetamine challenge. Before tamoxifen, control
and GLS1 iHET mice did not differ in their response to amphetamine. One month after
tamoxifen treatment, amphetamine-induced hyperlocomotion was blocked in GLS1 iHET
mice. The block was largely maintained after 5 months. Thus, a genetically induced
glutaminase reduction—mimicking pharmacological inhibition—strongly attenuated the
response to a propsychotic challenge, suggesting that glutaminase may be a novel
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target for the pharmacotherapy of schizophrenia. These results demonstrate how
genetic pharmacotherapy can be implemented to test a CNS target in advance of
the development of specific neuroactive inhibitors. We discuss further the advantages,
limitations, and feasibility of the wider application of genetic pharmacotherapy for
neuropsychiatric drug development.
Keywords: glutamate, glutamine, GLS1, tamoxifen-inducible, allelic abundance, antipsychotic
INTRODUCTION
Genetic pharmacotherapy—the use of genetic intervention to
achieve a pharmacological effect—has been proposed as an early
drug development strategy for the identification of novel CNS
targets in mouse models prior to the development of specific
ligands (Gellman et al., 2011). This strategy offers particular
advantages for proof-of-concept studies for CNS disorders.
Currently, identifying drug candidates for CNS disorders
requires not only designing specific high-affinity ligands, with
minimal off-target effects, but also that the ligands permeate
the blood-brain barrier. Genetic pharmacotherapy obviates these
ligand-development requirements by utilizing tamoxifen as a
wild-card ligand, with excellent brain permeation, and achieves
perfect specificity through genetically controlled knockdown of
the gene of interest.
Genetic pharmacotherapy employs ubiquitous and temporally
controlled genetic blockade to simulate systemic drug treatment
in adulthood. Both the global and temporal aspects of this
strategy can be achieved by breeding a global tamoxifen-
inducible cre mouse line, in which ERT2cre is under the control
of a strong ubiquitous promoter, with a mouse line in which the
gene encoding the molecular target of interest is floxed. Utilizing
heterozygous floxed mice enables end-stopping the induced
deficiency at about 50%, matching the range of inhibition
achieved by most drugs used in the treatment of psychiatric
disorders (Farde et al., 1992; Hirano et al., 2005). Despite the
apparent advantages of the genetic pharmacotherapy strategy, its
success in uncovering new targets for the treatment of psychiatric
disorders has not been tested.
Identifying novel therapeutic targets for the treatment of
schizophrenia (SCZ) has been particularly challenging. Despite
the increasing impetus for glutamate-based pharmacotherapies
for SCZ, none have yet proven successful (Moghaddam and Javitt,
2012). Plausible explanations are that current glutamatergic
pharmacotherapeutic targets do not achieve the necessary
modulation of aberrant synaptic activity or do not target
key brain circuits selectively. Targeting glutamate synaptic
transmission presynaptically has therapeutic potential (Conn
et al., 2009). Metabotropic mGluR2/3 agonists attenuate both
PCP-induced glutamate release and PCP-induced psychomotor
stimulation (Moghaddam and Javitt, 2012). This preclinical
work culminated in the demonstration of significant clinical
promise for the mGluR2/3 agonist LY214002 in early clinical
trials (Patil et al., 2007); however, this was not borne out
in subsequent studies (Adams et al., 2014; Downing et al.,
2014), although subtype selective modulation holds considerable
promise (Walker and Conn, 2015).
An alternate presynaptic glutamate-based approach involves
inhibiting glutamate recycling. Metabolic studies indicate that
the majority of synaptically released glutamate is synthesized or
recycled from glutamine via the action of glutaminase (Albrecht
et al., 2010; Rothman et al., 2011), and electrophysiological
studies indicate that excitatory synaptic transmission can be
attenuated by inhibition of glutaminase (Tani et al., 2014).
Consistent with this, homozygous stopGLS1 mice (GLS1
knockout mice) die shortly after birth, apparently due to
altered rhythmic activity in respiratory centers (Masson et al.,
2006). In culture, homozygous stopGLS1 neurons show normal
spontaneous excitatory synaptic activity, but more pronounced
synaptic fatigue when stimulated at higher frequency, consistent
with the glutamate recycling function of glutaminase. In adult
hippocampal slices, excitatory transmission is modulated by
reducing or enhancing glutamine, dependent on time (Kam and
Nicoll, 2007) and patterns of synaptic activity (Tani et al., 2014).
Thus, glutaminase inhibition is likely to attenuate high-frequency
excitatory activity preferentially.
Examining mouse models with resilience—rather than
disease—phenotypes offers a more direct approach to identifying
therapeutic targets for complex neuropsychiatric disorders
(Mihali et al., 2012). Remarkably, heterozygous stopGLS1 mice
(GLS1 HETs), with only one functional GLS1 allele, manifest
a SCZ resilience phenotype (Gaisler-Salomon et al., 2009a),
with diminished responsiveness to propsychotic amphetamine
challenge and reduced amphetamine-induced dopamine release.
On brain imaging, GLS1 HET mice show hypoactivity in
hippocampal CA1, inverse to that seen in the clinical studies,
as well as attenuated ketamine-induced frontal cortex activation
(Gaisler-Salomon et al., 2009b). Taken together these findings
suggest that systemic administration of glutaminase inhibitors
might prove therapeutic in SCZ. Importantly, partial inhibition
of glutaminase appears to have a benign side-effect profile, as
GLS1 HETs are remarkably normal in a wide-ranging battery
of behavioral tests of baseline behavior (Gaisler-Salomon et al.,
2009a). They do have a subtle cognitive phenotype, with
a reduction in delayed context-dependent fear conditioning
(Gaisler-Salomon et al., 2009a), with adult onset (Gaisler-
Salomon et al., 2012), and an enhancement in trace fear
conditioning (Hazan and Gaisler-Salomon, 2014). The lack
of high potency brain-penetrant glutaminase inhibitors has
precluded testing glutaminase inhibition as a pharmacotherapy
for SCZ.
Here we have implemented a genetic pharmacotherapy
strategy for the first time in the CNS to ask whether reducing
GLS1 expression to heterozygous levels in adult mice would
block the behavioral response to propsychotic amphetamine
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challenge. There are three steps in the strategy. In the first step,
we made floxGLS1 mice, in which exon 1 of GLS is susceptible
to cre-dependent recombination to reduce GLS1 expression,
and bred these mice with global inducible deletor CAGERT2cre
mice, in which the CAG promoter drives tamoxifen-inducible
cre expression to enable pharmacological inhibition to about
50%. In the second step, we show in the resulting progeny that
tamoxifen (Tmx) induces full recombination of the floxGLS1
allele, and reduction in GLS1 expression to about 50%. In the
third step, we ask whether the induced GLS1 reduction attenuates
amphetamine-induced hyperlocomotion.
MATERIALS AND METHODS
Mice
Procedures involving mice and their care were conducted in
accordance with the guidelines of the National Institutes of
Health Guide for the Care and Use of Laboratory Animals,
under protocols approved by the Institutional Animal Care and
Use Committees of Columbia University and New York State
Psychiatric Institute. Matched littermates were used as controls.
Experimental mice were 50:50 C57BL/6J:129J background. Both
sexes were used, in roughly equal proportions for molecular
studies; male mice were used for behavioral studies.
Generation Of Conditional GLS1 Hets
Conditional GLS1 mice were made by introducing one-loxP
site into exon 1 and a floxed PGK-neo cassette into intron
1 (Figure 1A1). The SphI-HindIII targeting vector of 5.4 kb
inserted in exon 1 contained a loxP site 16 bp before the initiating
codon and a floxed 1018 bp neomycin-resistance (neo) cassette
in intron 1. The three-loxP sites were in reverse orientation. The
loxP site before the ATG was inserted into a unique XhoI site that
was created by site-directed mutagenesis. A KpnI site was added
at the 5′ end of the oligonucleotide coding for the loxP site, and a
HindIII site was added in the floxed PGK-neo cassette to facilitate
subsequent screening by Southern analysis, after electroporation
of the targeting vector into embryonic stem (ES) cells. Southern
blot analysis used a 32P-labeled external probe (Probe A: 336 bp
genomic probe 5′ of the targeting construct; Figure 1A2).
Chimeric 3-loxP mice resulting from the implantation of
selected ES cell clones were bred to wild-type (WT) mice
for one generation and then crossed to EIIacre universal
partial deletor mice (Holzenberger et al., 2000); F1 progeny
(mosaic mice) were bred with wild-type mice (Taconic, strain
129JS6/SvEvTac) to obtain progeny with the 3-loxP allele,
the 2-loxP allele, or 1-loxP (delta allele; Figure 1B1). F2
progeny with the desired 2-loxP allele were identified by
PCR genotyping. The 5′ loxP site was identified by forward
primer (Primer X) GCCCCAAGCATCCTCATCTCGAATA and
reverse primer (Primer Y) TAAGAGCAGCTCCCGTAGCA; the
3′ loxP site was identified by forward primer (Primer A)
GGCCTGCTTAATGTTTCCTG and reverse primer (Primer C)
GGCATATCCCTGAGTTCGAG (Figure 1B2). GLS1lox/+ mice
were bred to generate GLS1lox/+ and GLS1lox/lox mice for
assessment of genotypic impact of flox status on GLS1 mRNA
expression.
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FIGURE 1 | Generation of conditional floxGLS1 mice. (A) Insertion of
3-loxP construct into the GLS1 gene. (A1) A targeting construct engineered
with loxP sites flanking exon 1 (thick black line with transcription start ATG
codon indicated) of the GLS1 gene encoding glutaminase was inserted into
the endogenous GLS1 locus by homologous recombination. The targeting
vector (green) also contained a floxed PGK-neo-cassette (thick blue line) for
positive selection of the ES cell clones. The blue bar indicates the position of
external Probe A (blue), used for Southern analysis, while the black arrow
indicates the length of the expected wild-type band and the red arrow the
length of the expected mutant band. Note that an additional HindIII site was
introduced along with the middle loxP site. (A2) In a HindIII digest of ES cell
DNA, Probe A hybridized to a 6.5 kb band for the WT allele, in contrast to a
5.0 kb band for the 3-loxP allele. Results are shown for ES cells with
non-homologous recombination (NHR) and homologous recombination (HR).
(B) Breeding floxGLS1 mouse. (B1) 3-loxP mice were crossed with EIIacre
partial deletor mice to remove the floxed PGK-neo cassette. 2-loxP progeny
were identified by PCR genotyping using two primer pairs flanking the loxP
sites. Blue bars indicate the location of the primers. (B2) The PCR gels show
genotyping results for two mice. In the top gel, the 5′ loxP site was revealed by
a 214 bp band, in addition to the WT allele of 157 bp in the mutant mouse
(2-loxP). In the bottom gel, the 3′ loxP site was revealed by a 430 bp band, in
(Continued)
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FIGURE 1 | Continued
addition to the WT and of 341 bp in the mutant mouse. (C) GLS1 mRNA
expression from the floxGLS1 allele. mRNA was measured in whole
hippocampus (Hipp) and frontal cortex (FC) tissue. Relative expression was
normalized to the corresponding WT mice (dashed line), done in two cohorts
of mice, lox/+ and lox/lox mice. There was no genotypic impact of GLS1 flox
status on GLS1 mRNA. The number of samples is indicated above the bars
(gray numbers correspond to the lox/+ cohort and black numbers correspond
the lox/lox cohort).
Generation of Inducible GLS1
Heterozygous Mice
We used Tmx-inducible CAGERT2cre (Hayashi, 2002)
mice obtained from The Jackson Laboratory [JAX; strain
B6.Cg-Tg(Cag-cre/Esr1∗)5Amc/J; Stock number 004682].
CAGERT2cre/+ mice were first bred with a enhanced yellow
fluorescence (EYFP) reporter mouse Rosa26sfEYFP/+[JAX,
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J; stock number
006148] to confirm ubiquitous cre expression. The genotyping
of these mice was done following the JAX protocol and primers.
The CAGERT2cre/+ mice were then crossed with GLS1lox/lox
mice, to obtain experimental GLS1 iHET and control mice. For
genotyping, we used the previously described forward Primer
A and reverse Primer C for the floxed allele and Primer X and
reverse Primer C for the delta allele.
RNA Extraction and Reverse Transcription
Quantitative PCR (RT-qPCR)
Brain tissue was flash-frozen in 300µl of Qiazol (Qiagen), a
RNase-inhibitor buffer. RNA extraction was done using the
RNeasy Lipid Mini Kit (Qiagen), according to the manufacturer’s
instructions and stored in RNase-free water at −80◦C. RT-qPCR
was performed as described previously (Gaisler-Salomon et al.,
2012). Briefly, RNA concentrations were standardized to 1µg
per 10µl water using a NanoDrop 1000 Spectrophotometer
(ThermoScientific, Waltham, MA). The 260:280 nm absorbance
ratio was measured to assess RNA quality; samples were excluded
if the ratio was outside the range 2.0 ± 0.2, or if the RNA
concentration was too low. Genomic DNA was removed by
digestion with 1µl DNase (Promega). Reverse transcription was
carried out using a High Capacity cDNA Reverse Transcription
kit (Applied Biosystems). Reverse transcription product (cDNA)
was diluted to a volume of 1ml in water. qPCR was performed
using an Opticon 2 DNA Engine (Bio-Rad) and GPDH primers
(forward: AACTCCCACTCTTCCACCT; reverse: CACCACCC
TGTTGCTGTA) and GLS1 primers (forward: GTACAGTCTC
TGTGGCTTGG; reverse: CAGTTAGCGGCTCATTCAC). The
cycle threshold (Ct) values for GLS1 gene were normalized
to GAPDH (1Ct). Relative copy number was obtained by
exponentiation of1Ct values (function 2−1CT)
Tamoxifen Administration
A 10mg/ml Tmx solution was prepared by solubilizing 125mg
tamoxifen (Sigma-Aldrich, T5648) in 1.25ml 100% ethanol and
then 11.25ml peanut oil (Sigma-Aldrich, P2144). The mixture
was vortexed for 5min and incubated for >6 h at 37◦C. Animals
received 0.1mL i.p. (1mg Tmx) daily for 5 successive days.
Immunohistochemical Visualization of
EYFP Expression
Mice (Rosa26fsEYFP/+:: CAGERT2cre/+ or Rosa26fsEYFP/+) were
perfused with cold PBS followed by 4% paraformaldehyde
(PFA), the brains removed, post-fixed overnight in 4% PFA,
and cryoprotected in 30% sucrose. Brains were then cut using
a cryostat. Sections (50µm) were washed in PBS (100mM; pH
7.4) and incubated in glycine (100mM) for 30min to quench
aldehydes. Non-specific binding was blocked with 10% normal
goat serum (NGS; Millipore) in 0.1% PBS Triton X-100 for
2 h (PBS-T). Sections were incubated with primary antibody,
anti-GFP (1:2000 dilution; rabbit polyclonal antibody; Millipore,
AB3080) in 0.02% PBS-T and 2% NGS at 4◦C for 24 h, then
washed with PBS and incubated for 45min with anti-rabbit Alexa
Fluor 488 (1:200 dilution; Invitrogen) in 0.02% PBS-T. Sections
were mounted on slides and cover slipped using Prolong Gold
aqueous medium (Invitrogen) and stored at 4◦C. Fluorescence
images were acquired with a Fluoview FV1000 confocal laser
scanning microscope (Olympus) with a 20x objective.
Quantitative GLS1 Genotyping
The left hippocampus of Control and GLS1 iHET mice was used
for quantitative genotyping (and the right for RNA expression).
Tissue was sent to Transnetyx (Cordova, TN) in 96-well plates
for genotyping using probe-based quantitative PCR (qPCR).
Allelic abundance was obtained from the mean of 4 qPCR
determinations (2 runs done in duplicate). The conditional
floxGLS1 and wild-type allele signals were normalized to the one-
allele signal from control (GLS1lox/+) mice that had not received
Tmx.
Amphetamine-Induced Hyperlocomotion
Control and GLS1 iHET mice were handled for 5min daily for
3 days prior to amphetamine challenge. Locomotor activity and
rearing was measured using SmartFrame Open Field Stations
(Kinder Scientific) equipped with infrared beams at 2 different
heights; each break of a lower beam represents an ambulatory
count, while each break of a upper beam represents a rearing
count. We also measured fine movements, defined as beam
breaks that do not reflect the relocation of the mouse position in
the open field, and that are sensitive to movements like grooming
and head weaves or bobs. On the test day, mice were put in the
open field for 1 h, then administered amphetamine 2mg/kg via
intraperitoneal injection and returned immediately to the open
field, and monitored for the subsequent 2 h. D-Amphetamine
hemisulfate (Sigma-Aldrich) was dissolved in normal saline.
Statistical Analysis
The data for allelic abundance and mRNA expression were
analyzed using a genotype x Tmx treatment factorial ANOVA.
Significant interactions were analyzed further for simple main
effects using the error terms from the specific analyses. The
percentage of control mRNA values in the hippocampus were
analyzed using a one-way ANOVA followed by the LSD post-hoc
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test. The percentage of control mRNA values for the Tmx-
Treated groups were analyzed using a brain region x time (post-
Tmx injection) ANOVA. Behavioral data recorded in bins of
10min during the 3 h open field session were analyzed separately
for each Tmx treatment using factorial ANOVA with genotype
as the between-subjects factor and time (bin) as the within-
subjects repeated measures factor. Total locomotion in response
to amphetamine was used to compare between treatments
(No-Tmx and Tmx-Treated, at the 30 day time point) using
genotype × treatment factorial ANOVA. Significant interactions
were further analyzed for simple main effects using the error
terms from the specific analyses. Total locomotion in response
to amphetamine of Tmx-Treated mice at the 30 and 146 day time
points was analyzed using a repeated measures ANOVA.
RESULTS
Conditional floxGLS1 Mice
We generated conditional floxGLS1mice by knocking in a 3-loxP
cassette (Targeting vector), with lox P sites flanking the coding
sequence of GLS1 exon 1, followed by a floxed PGK-neo cassette
(Figure 1A1). ES cells with successful recombination events were
identified by Southern analysis of a HindIII restriction digest. An
external probe, Probe A, identified a band of genomic DNA of
5 kb in ES cells showing homologous recombination, in contrast
to a band of 6.5 kb in WT ES cells (Figure 1A2). Southern
analysis of a KpnI restriction digest with Probe A identified a
band of 4.9 kb in ES cells showing homologous recombination,
in contrast to a band of 7.2 kb in WT ES cells (data not shown).
The PGK-neo cassette was removed by breeding 3-loxPmice with
EIIacre universal partial deletor mice (Holzenberger et al., 2000)
and genotyping the progeny for the desired 2-loxP floxGLS1
allele (Figure 1B1). The 5′ loxP site was identified with Primers X
and Y, yielding a mutant band containing the loxP site of 214 bp,
in contrast to aWT band of 157 bp. The 3′ loxP site was identified
with Primers A andC, yielding amutant band containing the loxP
site of 430 bp, in contrast to a WT band of 341 bp (Figure 1B2).
Analysis of GLS1 mRNA revealed no genotypic impact of flox
status (Figure 1C), in both the hippocampus [F(2, 31) = 0.08,
p = 0.93] and frontal cortex [F(2, 27) = 0.68, p = 0.51].
To enable Tmx-induced recombination of the floxGLS1
allele, we used CAGERT2cre global-inducible deletor mice. To
demonstrate universal cre induction, we first bred the mice with
Rosa26fsEYFP EYFP reporter mice. After Tmx, Rosa26fsEYFP/+::
CAGERT2cre/+, but not Rosa26 fsEYFP/+, mice showed widespread
EYFP expression in all brain areas imaged (Figure 2A). Then,
we crossed CAGERT2cre/+ mice with GLS1lox/lox mice to produce
experimental GLS1 inducible-Het (GLS1 iHET), CAGERT2cre/+::
GLS1lox/+ mice and Control GLS1lox/+ mice. We used PCR
screening to detect the presence of WT, floxed and recombined
(1) alleles (Figure 2B). The PCR gels of tail samples showed that
prior to Tmx, WT and floxed allele bands were present in both
Control (n = 5) and GLS1 iHET (n = 8) mice (Figure 2C1, left).
After Tmx, PCR gels from GLS1 iHET mice showed complete
elimination of the floxed allele band, while PCR gels from control
mice continued to show both the WT and floxed allele bands
(Figure 2C1, right).
To ask whether there was recombination prior to Tmx, we
looked for the presence of the 1 allele band in tails samples
(Figure 2C2), identified as a 390 bp band with Primers X and
C. Although the 1 band was not present in control mice, there
was a prominent 1 band in Tmx-naïve GLS1 iHET mice. Since
PCR gels are not quantitative, this revealed only that there was
some “leaky” cre recombination prior to Tmx administration in
tail samples, but did not provide quantitative information about
the magnitude of the leakiness.
Conditional GLS1 Reduction in the Brain
To assess the effect of Tmx treatment in the brain of GLS1
iHET mice, we measured GLS1 allelic abundance by quantitative
genotyping with RT-qPCR, in the whole hippocampus from one
hemisphere of Tmx-naïve (No-Tmx) mice at P60 and Tmx-
Treated-21 d mice (P81), 21 days post-Tmx.We compared No-
Tmx Control mice (n = 7) and GLS1 iHET mice (n = 7) to
Tmx-Treated-21 d Control (n = 6) and GLS1 iHET mice (n = 5;
Figure 3A). As expected, WT allelic abundance did not change;
there was no significant genotypic [F(1, 21) = 3.98, p = 0.06] or
Tmx treatment [F(1, 21) = 1.13, p = 0.30] effect, and there were
no significant interactions [F(1, 21) = 0.77, p = 0.39]. Floxed
GLS1 allelic abundance was lower in the GLS1 iHETmice prior to
Tmx and nearly eliminated post-Tmx. Factorial ANOVA revealed
a significant effect of genotype [F(1, 21) = 42.05, p < 0.0001]
and treatment [F(1, 21) = 6.03, p = 0.02], but no significant
interaction [F(1, 21) = 3.16, p = 0.09], consistent with “leaky”
cre recombination. In GLS1 iHET No-Tmx hippocampal tissue
there was a 43% decrease in floxed GLS1 allelic abundance,
corresponding to 77% functional GLS1 abundance. Post-Tmx,
there was an 88% decrease in floxed GLS1 allelic abundance,
corresponding to 56% functional GLS1 abundance.
We then measured GLS1 mRNA expression in the other
hippocampi of the same mice used for the RT-qPCR allelic
abundance determination, combined with hippocampi from
Tmx-Treatedmice used in the behavioral experiment (see below).
We compared No-Tmx, Control (n = 7; GLS1 iHET, n = 7)
to Tmx-Treated-21 d (Control, n = 3; GLS1 iHET, n = 4)
and Tmx-Treated-148 d (Control, n = 7; GLS1 iHET, n = 7;
Figure 3B1). Factorial ANOVA revealed a significant genotype
x treatment interaction [F(1, 28) = 6.61, p = 0.004]. Among
treatment conditions, there was no genotype effect in the No-
Tmx group [F(1, 11) = 0.79, p = 0.39], but a significant genotype
effect in the Tmx-Treated-21 d group [F(1, 5) = 462.07, p <
0.0001] and the Tmx-Treated-148 d group [F(1, 12) = 9.33, p =
0.01]. Despite some “leaky” recombination, these results revealed
that there was no genotypic impact on GLS1 mRNA levels prior
to Tmx treatment.
GLS1 mRNA increased significantly in Control mice
[F(1, 14) = 14.465, p < 0.001], but not in GLS1 iHET mice
[treatment effect: F(1, 14) = 3.417, p = 0.06]. The increase in
Control mice was likely due to the different ages of the three
groups: No-Tmx were P60; Tmx-Treated-21 d were P81 (21
days older), and Tmx-Treated-148 d ranged from P218–P282
(∼5 months older). To avoid the age confound, we analyzed
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brain section schematic (left). Confocal images revealed ubiquitous EYFP expression in CAGERT2cre/+:: Rosa26fsEYFP/+, but not Rosa26fsEYFP/+ mice. (B) Primer
strategy used to determine the presence of WT, floxed, and recombined (1) GLS1 alleles. Blue bars indicate the locations of the three primers used. Black arrow
indicates length of the amplified WT allele, the red arrow the floxed allele and the green arrow the recombined (1) allele. (C) PCR genotyping of tail samples from
control and GLS1 iHET mice pre- and post-Tmx. Gels from two mice of each genotype are shown, with mouse identification numbers. Band sizes are shown to the
right of the gels. (C1) Gel electrophoresis (left) showed both floxed and WT DNA bands (with Primers A,C) prior to Tmx (Pre-Tmx) administration in GLS1 iHET and
Control mice, whereas post-Tmx (right), the floxed DNA band remained in Control (GLS1lox/+) mice, but was eliminated in GLS1 iHET mice. (C2) Gel electrophoresis
with Primers X, C identified the presence of a 1 allele in GLS1 iHET mice prior to Tmx treatment, revealing “leaky” cre-mediated recombination.
normalized ratios of GLS1 mRNA expression (Figure 3B2,
right). This revealed that GLS1 mRNA expression in the
hippocampus was reduced to 46% in Tmx-Treated-21 d mice
and to 68% in Tmx-Treated-148 d mice. A one-way ANOVA
showed a treatment effect [F(2, 14) = 6.865, p = 0.008). LSD
post-hoc revealed that mRNA expression ratios in No-Tmx
mice were different from Tmx-Treated-21 d (p = 0.004) and
Tmx-Treated-148 d mice (p = 0.015), but there was no statistical
difference between Tmx-Treated-21 d and Tmx-Treated-148 d
mice (p = 0.294). A similar reduction was seen in the frontal
cortex, 50% in Tmx-Treated-21 dmice and 78% in Tmx-Treated-
148 d mice (Figure 3B2, left), consistent with an induced global
reduction in GLS1 expression to heterozygous levels. ANOVA
results comparing the mRNA values between hippocampus
and frontal cortex of Tmx-Treated mice at the two time points,
revealed a main effect of time [F(1, 18) = 10.47, p = 0.005], but
not brain region [F(1, 18) = 0.569, p = 0.46], nor a brain region
x time interaction [F(1, 18) = 0.024, p = 0.46], suggesting that
after 5 months there was some recovery of function at the mRNA
level.
Amphetamine-Induced Hyperlocomotion
We then asked whether adult-induced glutaminase deficiency
would attenuate amphetamine-induced hyperlocomotion. We
compared two cohorts of mice: No-Tmx Control (n = 6) and
GLS1 iHET mice (n = 8; Figure 4A), and Tmx-Treated Control
(n = 5) and GLS1 iHET mice (n = 9; Figure 4B). Tmx-
Treated mice (age range P74–P141) received Tmx 1mg daily,
for 5 days, and were tested 30 days after the last Tmx injection
(age range P117–P174), and then again after 146 days (age range
P226–P283). There was no genotypic difference in the weight of
Tmx-treated mice at 30 days post-Tmx (Control, 34.78 ± 1.88 g;
GLS1 iHET, 36.14 ± 1.3 g; p = 0.611) nor at 146 days (Control,
39.54± 2.89 g; GLS1 iHET, 42.31± 1.2 g; p = 0.283).
Mice were allowed to habituate to the open field for 1 h.
Although Control Tmx-treated-30 d mice appeared to be more
active during habituation than Tmx-treated-30 d GLS1 iHET
mice, the difference was not significant. During habituation, there
was no significant genotype × time interaction in the three
groups of mice: for No-Tmx mice [ANOVA with time as the
repeated measure factor, F(1, 12) = 0.27, p = 0.61; Figure 4A],
Tmx-Treated-30 d mice [F(1, 12) = 0.52, p = 0.82; Figure 4B1],
or Tmx-Treated-146 d mice [F(1, 12) = 0.432, p = 0.43;
Figure 4B2].
After habituation, mice received amphetamine (2mg/kg) and
were monitored for 2 h. There was no significant genotype ×
time interaction in No-Tmx mice [ANOVA with time as the
repeated measure factor, F(11, 132) = 0.673, p = 0.76; Figure 4A],
but a significant interaction in Tmx-Treated mice, at both 30
days [F(11, 132) = 2.629, p = 0.005 Figure 4B1] and 146
days post-Tmx [F(11, 132) = 2.215, p = 0.02; Figure 4B2].
To compare the amphetamine effect between No-Tmx and
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Tmx-Treated-30 d mice directly, we analyzed total locomotor
activity in the hour after amphetamine administration. There was
a robust genotype × treatment interaction [factorial ANOVA,
F(1, 24) = 6.436, p = 0.018; Figure 4C1, right]. Among treatment
groups there was a significant effect of genotype in the Tmx-
treated-30 d mice [F(1, 12) = 35.916, p < 0.0001] but no
genotype effect in the No-Tmx mice [F(1, 12) = 0.07, p = 0.93].
Among genotypes, there was a treatment effect for the GLS1
iHET mice [F(1, 15) = 5.59, p = 0.03], but not for the Controls
[F(1, 9) = 1.81, p = 0.21]. Thus, adult induction of GLS1
deficiency blocked amphetamine-induced hyperlocomotion. The
attenuated locomotor response to amphetamine persisted for
several months (Figure 4C1, left). Analysis of total locomotion
in response to amphetamine with time (30 vs. 146 days) as the
repeated measures factor revealed a genotype effect [F(1, 12) =
23.9, p = 0.0003], but no time effect [F(1, 12) = 0.91, p = 0.36] or
time x genotype interaction [F(1, 12) = 2.14, p = 0.17].
To address whether the blunted locomotor response to
amphetamine in GLS1 iHET mice could have arisen as a
result of increased sensitivity to psychostimulants manifest as
an induction of stereotyped behaviors, we analyzed rearing
and fine movements in the Tmx-treated mice. We found that
total rearing counts following amphetamine did not differ
between genotypes [F(1, 12) = 3.20, p = 0.09], while total
fine movements were lower in the GLS1 iHETs [F(1, 12) =
16.76, p = 0.01]. Since there was no increase in rearing
or fine movements in the GLS1 iHET mice, Tmx-treated
GLS1 iHET mice were indeed less sensitive to amphetamine,
and that this was not due to induction of stereotyped
behaviors.
We compared the relative amphetamine-induced
hyperlocomotion of Tmx-Treated-30 d and Tmx-Treated-
146 d mice (Figure 4C2). Hyperlocomotion was calculated
by integrating total locomotion after subtracting the average
baseline locomotion in the 20min preceding the amphetamine
injection. This revealed that Tmx-treated-30 d GLS1 iHET
mice showed only 5% hyperlocomotion relative to Control
mice. When tested again after 5 months, Tmx-Treated-146 d
GLS1 iHET showed 25% hyperlocomotion; this increase was
not significant [ANOVA, with time as a repeated measures
factor, F(1, 8) = 1.1, p = 0.32]. Thus, the induced GLS1 allelic
reduction had a persistent effect on amphetamine-induced
hyperlocomotion, commensurate with chronic inhibition
pharmacotherapy.
DISCUSSION
Evaluation of brain targets for the pharmacotherapy of
neuropsychiatric disorders has been hampered by the lack of safe,
specific, high-affinity, brain-penetrant inhibitors. Glutaminase
is one such target, where strong evidence suggests that
heterozygous reduction in glutaminase activity confers a
schizophrenia resilience phenotype in mice, while at the same
time having a benign side effect profile (Gaisler-Salomon
et al., 2009a). Here we sought to use genetic pharmacotherapy
to test whether glutaminase inhibition therapy would block
propsychotic effects of amphetamine, a dimension of the
schizophrenia resilience profile of GLS1 Het mice. We generated
floxGLS1 mice to enable conditional genetic reduction of
glutaminase expression in adulthood, and thus to reduce
glutaminase activity to the level in constitutive GLS1 Het
mice (Masson et al., 2006; Gaisler-Salomon et al., 2009a). We
bred floxGLS1 mice with global inducible cre-deletor mice
to generate GLS1 iHET mice, in which Tmx becomes an
irreversible glutaminase inhibitor, and measured amphetamine-
induced hyperlocomotion as a proxy for positive symptoms
of schizophrenia (Arguello and Gogos, 2006; van Den Buuse,
2010). In Tmx-treated GLS1 iHET mice, amphetamine-induced
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FIGURE 4 | Attenuation of amphetamine-induced hyperlocomotion in
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amphetamine-induced hyperlocomotion, 30 days post-Tmx. Factorial ANOVA
revealed a significant genotype × time effect of amphetamine (p < 0.05), but
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FIGURE 4 | Continued
no difference prior to amphetamine. (B2) The reduction in
amphetamine-induced hyperlocomotion persisted 146 days post-Tmx. (C)
Total locomotion after amphetamine injection. (C1) Tmx-naïve (No-Tmx) mice
showed no genotypic difference in their overall response to amphetamine,
whereas Tmx-Treated control mice differed significantly from GLS1 iHET mice
30 days post-Tmx (left graph). *indicates a significant genotypic difference,
p < 0.05. The amphetamine-induced locomotion of Tmx-Treated mice did not
change 146 days post-Tmx treatment. ## indicates a main effect of
genotype, p < 0.001; but no main effect of time or significant interaction. (C2)
AMPH-induced hyperlocomotion expressed as an increase in locomotion
above baseline. Tmx-Treated GLS1 iHET mice showed a minimal response to
amphetamine at 30 days post-Tmx (5% increase in locomotion in response to
AMPH), and a modest response at 146 days (25%).
hyperlocomotion was blocked, consistent with the therapeutic
potential of glutaminase inhibition.
Generation of floxGLS1 Mice
We made conditional GLS1 mice by floxing the GLS1 coding
sequence in GLS1 exon 1. GLS1 mRNA levels were unaffected in
heterozygous, as well as homozygous floxGLS1 mice indicating
that the floxGLS1 allele is a silent mutation. In contrast, GLS1
knockout mice die shortly after birth due to respiratory failure,
apparently the result of altered patterns of respiratory rhythms
in brainstem respiratory centers (Masson et al., 2006). In a
preliminary experiment, we have found that inducible GLS1
knockout mice, GLS1 iHOM (CAG ERT2cre/+:: GLS1lox/lox) mice
(Control, n = 2; Tmx-treated, n = 2) develop a severe
neurological syndrome about 3 weeks post-Tmx, revealing
the necessity of glutaminase function in adulthood. This
observation further indicated that cre-mediated recombination
of the floxGLS1allele produced a delta (knockout) allele,
and that 1 month post-Tmx was sufficient for induction of
glutaminase deficiency. While this project involved generating a
floxGLS1 mouse line, this first step in the implementation of a
genetic pharmacotherapy strategy for other CNS targets is now
increasingly facile, as floxed mouse lines have been generated
for the majority of mouse genes through the Knockout Mouse
Project (www.komp.org), including for GLS1 (Skarnes et al.,
2011), and floxed mouse lines can be rapidly generated using
CRISPR-Cas genome engineering (Yang et al., 2014).
Validation of GLS1 iHET Mice
GLS1 iHET mice showed full recombination following Tmx
activation of CAGERT2cre, as evidenced by complete loss of the
floxed GLS1 allele. However, they showed significant leakiness,
with about 50% recombination in the absence of Tmx, and a
25% reduction in functional allelic abundance. At the point of
Tmx treatment in adulthood, this leakiness had not impacted
mRNA levels; post-Tmx, mRNA levels went down to about 50%.
Constitutive GLS1 HET mice show a similar 50% reduction
in mRNA (Gaisler-Salomon et al., 2012), corresponding to
a >50% reduction in glutaminase activity (Gaisler-Salomon
et al., 2009a). However, ex vivo measurement of glutaminase
activity does not reflect in vivo glutaminase activity, which is
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subject tomultimodal modulation due to end-product inhibition,
substrate availability, and phosphate modulation (Curthoys and
Watford, 1995). Rather, ex vivo activity reflects the amount of
glutaminase protein present, reported by its maximal activity.
Evaluating glutaminase inhibition in vivo requires tracking 13C-
precursor flux through astrocytes to neurons and the conversion
of glutamine to glutamate by magnetic resonance spectroscopy
(Patel et al., 2010; El Hage et al., 2012).
To generate a genetic intervention that mimics a
pharmacological effect, our strategy requires cre activation
with a ubiquitous promoter that only produces recombination
after Tmx administration. The progressive recombination
due to leakiness found in this study limits the tractability
of a strategy with CAGERT2cre mice, and highlights the
importance of measuring recombination prior to Tmx
administration when using inducible mouse lines. Other
ubiquitous inducible promoters should be essayed, such as
ROSAERT2cre (Ventura et al., 2007) and UBCERT2cre (Ruzankina
et al., 2007). However, these promoters are weaker and may
not achieve full recombination of some floxed alleles. Breeding
mice homozygous for the ERT2cre allele would be one way to
increase the efficacy of weaker promoters. Another way would
be improved delivery of Tmx by solubilization of Tmx with
hydroxybutenyl-cyclodextrin (Buchanan et al., 2006).
Testing Whether Induction of Glutaminase
Deficiency is Potentially Therapeutic
To test the efficacy of adult-onset glutaminase inhibition,
we chose a key dopamine-dependent behavioral phenotype
of constitutive GLS1 HETs, the attenuated response to pro-
psychotic amphetamine challenge (Gaisler-Salomon et al.,
2009a). Amphetamine-induced hyperlocomotion is a robust,
efficient test primarily involving dopaminergic and not
glutamatergic mechanisms. Repeated amphetamine produces
sensitization (Vezina, 2004), so the attenuation of amphetamine-
induced hyperlocomotion we found on the tests done
post-Tmx went counter to the expected increase with repeated
administration. Amphetamine-induced hyperlocomotion,
driven by increased dopamine release in the NAc (Sellings
and Clarke, 2003; Ikemoto, 2007), along with PPI (Powell
et al., 2009), which was unaffected in constitutive GLS1 HETs
(Gaisler-Salomon et al., 2009a), are the two tests with the best
face validity for positive symptoms in SCZ (Arguello and Gogos,
2006; van Den Buuse, 2010).
The low-dose Tmx dose regimen used (1mg daily for 5
days) has no persistent impact on a range of mouse behaviors,
examined 1 month post-Tmx (Vogt et al., 2008), and did not
attenuate amphetamine-induced locomotion, as seen in control
mice at the two post-Tmx time points tested. Low-dose Tmx
with a heterozygous CAT-ERT2cre allele should similarly limit
ERT2cre activation and minimize toxicity due to recombination
at pseudo-loxP sites (Higashi et al., 2009). The absence of
body weight differences between Control and GLS1 iHET mice
indicates that ERT2cre activation in the GLS1 iHETs did not
produce significant toxicity and per se did not reduce the response
to amphetamine. Having now shown that the floxGLS1 allele
is a silent mutation that does not impact gene expression,
further studies would be better controlled by varying flox status.
Evidently, limiting Tmx dosage to levels that would induce
efficient recombination of the gene of interest without inducing
significant Tmx or ERT2cre toxicity, and allowing a month for
recovery, will be crucial for successful implementation of genetic
pharmacotherapy.
With Tmx treatment, GLS1 mRNA levels in GLS1 iHET
mice went from normal to heterozygous levels. Prior to Tmx
treatment, Control and GLS1 iHET mice showed identical
responses to amphetamine. After Tmx treatment, and a sufficient
time interval to allow the impact of the allelic reduction to
translate into reduced mRNA levels and presumed protein
levels, there was a marked reduction in amphetamine-induced
hyperlocomotion (see Figure 5). This was the same marked
reduction we had seen in constitutive GLS1 HETs (Gaisler-
Salomon et al., 2009a), indicating that reduction of GLS1
to heterozygous levels in adulthood, was sufficient to reduce
amphetamine responsivity.
GLS1 iHOM mice could be used to access the whole dose-
response range by varying Tmx dose and the frequency of
administration to induce varying degrees of recombination,
extending to complete inhibition (as noted above this would
include lethality with full inhibition). However, the degree of
recombination, determined by allelic abundance, would need to
be assessed for every mouse, so larger cohorts would be required
to obtain sufficient numbers in the desired dose range. Moreover,
achieving a given inhibition in GLS1 iHOM mice would be
fraught with variability in the degree of recombination, not only
between animals, but also between different cell populations in
the same animal. So, utilizing GLS1 iHET mice, as we did here,
is the better strategy as it enables end-stopping glutaminase
inhibition to heterozygous levels.
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FIGURE 5 | Genetic pharmacotherapy for glutaminase inhibition. The
relative timing and magnitude of DNA, RNA, and behavioral effects are
schematized prior to and after Tmx treatment. Black dotted line shows
extrapolated DNA levels. Prior to Tmx, there was significant leaky
recombination, but this did not impact GLS1 mRNA levels or behavior
(amphetamine-induced locomotion). After Tmx, there was full recombination.
At short and long-time points post-Tmx, both mRNA levels and
amphetamine-induced hyperlocomotion showed the maximum effect at the
short-time point. As in constitutive GLS1 Hets, amphetamine-induced
hyperlocomotion was blocked at the short-time point, and strongly attenuated
at the long-time point.
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Genetic Pharmacotherapy as a Strategy
for Psychiatric Drug Development
Genetic intervention to achieve a pharmacological response,
which we term Genetic Pharmacotherapy (Gellman et al.,
2011), has been used widely outside the nervous system to
modulate pathogenic pathways and demonstrate therapeutic
efficacy, particularly in cancer research (Ruzankina et al., 2007;
Ventura et al., 2007; Higashi et al., 2009; Herranz et al., 2015),
but has not been used previously for CNS disorders. The
present study highlights the advantages of the approach for
neuropsychiatric drug development. Targets can be tested in
advance of formulating specific, brain-penetrant inhibitors. The
genetic intervention achieves perfect target specificity, with the
only off-target effects being those of Tmx, which are controlled
for by treating both control and genetically modified mice. The
present genetic pharmacotherapy study establishes the viability
of the strategy to identify new druggable targets for the treatment
of psychiatric disorders. Our initial evaluation suggests that
investment in molecular entities that inhibit glutaminase could
prove therapeutically effective. Further studies should address
other dimensions of the SCZ-resilience phenotype, and confirm
the benign side-effect profile of adult-induced global glutaminase
reduction.
Our results align with the finding that the recently-recognized
glutaminase inhibitor ebselen (Thomas et al., 2013) attenuates
amphetamine-induced hyperlocomotion (Singh et al., 2013).
Ebselen has also been shown to rescue prepulse inhibition
deficits in the neonatal ventral hippocampal lesion (NVHL)
rodent schizophrenia model (Cabungcal et al., 2014). In both
these reports, the putative mechanism of action involves ebselen
acting as a glutathione peroxidase mimic to reduce oxidative
stress (Sies, 1993). However, in vitro ebselen inhibits glutaminase
activity with an Ki of 0.015µM (Thomas et al., 2013), which
is almost 3 orders of magnitude better than the recognized
glutaminase inhibitor BPTES with an IC50 of 3µM (Thomas
et al., 2013) or the bromo-benzophenanthridinone compound
968, also with an IC50 in the low µM range (Wang et al., 2010),
arguing that its behavioral effects are mediated via glutaminase
inhibition. Thus, the ebselen data provide further support for the
therapeutic potential of glutaminase inhibition for schizophrenia,
and suggest that ebselen may have therapeutic potential in the
treatment of the disorder.
Genetic pharmacotherapy could be used to verify the targets
of known psychotherapeutic drugs though common actions on
phenotypic markers. The strategy tests chronic treatment, as we
have shown in the persistence of the behavioral effects in GLS1
iHETs months after Tmx treatment. In the case of the putative
action of ebselen as a glutaminase inhibitor, the action of the drug
could be compared to Tmx treatment of GLS1 iHET mice, and
the biomarker of glutamine flux through glutaminase measured
with 13C-MRS. Genetic pharmacotherapy could be applied to
mouse models with construct validity, such as mice carrying a
disease mutation, or models generated through developmental or
environmental interventions to reverse pathological phenotypes.
However, before the approach can be used effectively, global-
inducible promoters must be identified that show minimal
leakiness and yet achieve full cre-mediated recombination.
The strategy outlined here may be seen as a means to
stimulate serendipitous discovery of novel psychotropics—as a
genetically engendered resilience phenotype can be tested with
genetic pharmacotherapy to determine whether inhibition is
potentially therapeutic. The dearth of new psychiatric drugs
over the past decades underpins the vastly unmet need for
better treatments (Brundtland, 2001; Miller, 2010). Critics of
psychiatric drug development argue that because the etiology of
major mental illnesses remains so poorly understood, adequate
treatments cannot be developed (Conn and Roth, 2008). Using
genetic pharmacotherapy to test mouse models of disease
resilience promises to make a larger molecular landscape
accessible to drug discovery and enable more rapid testing of
psychopharmacotherapeutic targets.
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